Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490502 · ClinicalTrials.gov registry record · Phase 3
Vitamin D Supplementation in Multiple Sclerosis
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
NCT01490502: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT01490502 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 172 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01490502, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
Study Summary
Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks, and some research suggests that vitamin D could even be harmful to people with MS. In this clinical trial, patients with relapsing-remitting MS will receive high-dose or low-dose oral vitamin D in addition to an approved therapy for MS, glatiramer acetate. Patients will be evaluated for two years, and the effect of high-dose vitamin D supplementation on the rate of MS attacks and on the number of new lesions and change in brain volume on MRI will be determined. Establishing this association will have major implications for the treatment of individuals with MS throughout the world.
Interventions
- DRUG Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2012-03 |
| Est. Completion | 2021-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01490502
The ClinicalTrials.gov registry entry for NCT01490502 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT01490502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01490502 about?
NCT01490502 is a clinical study titled "Vitamin D Supplementation in Multiple Sclerosis". Low vitamin D levels have been shown to increase a person's risk of developing multiple sclerosis (MS), and patients with MS who have lower vitamin D levels are at increased risk of having attacks. However, it is not known if giving supplemental vitamin D to those with MS reduces the risk of attacks...
What is the current status of trial NCT01490502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2012-03. Estimated completion is 2021-05-15.
What interventions are being tested in trial NCT01490502?
The interventions under investigation include: Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT01490502?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.